Elekta stock holds steady as market values the radiotherapy backlog
Published on 08/21/2026 at 13:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Elekta AB (ISIN SE0000163628) stock traded at 55.25 SEK at the CBOE close on August 20, 2026, with a 5-day change of -0.99 percent and a year-to-date gain of 7.10 percent per recent market data. This places Elekta’s valuation in the mid-cap range for global oncology equipment providers and underscores a cautious but constructive stance toward its radiotherapy backlog.
Market data and valuation snapshot
Per the latest market overview for Elekta AB, the shares closed at 55.25 SEK on August 20, 2026, reflecting a modest short-term setback of -0.99 percent over the preceding five sessions while still delivering a 7.10 percent gain since the start of 2026. The combination of a mild recent pullback and solid year-to-date performance suggests investors are digesting prior gains as they await further clarity on earnings and guidance. A separate valuation table shows Elekta AB’s market capitalization at $1.879 billion, aligning the company with other mid-sized medical technology issuers in the global oncology and surgical equipment universe.
The comparison between Elekta’s current market cap of $1.879 billion and its recent share performance is important for investors assessing risk and reward in the broader cancer care equipment sector. While the stock price has risen 7.10 percent since January 2026, the valuation multiple embedded in that $1.879 billion market cap reflects expectations that Elekta can convert its installed base and order backlog into consistent cash flows and earnings growth over the coming quarters. The modest negative 5-day change of -0.99 percent indicates the market is not pricing in a sharp shock, but rather a period of consolidation.
Cash flow context and balance sheet discipline
Recent financial data compiled for Elekta AB highlight a detailed cash flow statement and related metrics that investors track closely when judging the sustainability of the business. The same market dataset that records the 55.25 SEK closing price also presents cash flow figures and other financial indicators, supporting a view that Elekta’s radiotherapy and radiosurgery portfolio continues to generate operating cash that can service debt, fund research and development and maintain its software and service offerings.
Historically, Elekta has emphasized recurring revenue streams from service contracts and treatment planning software layered on top of hardware sales. That business mix typically supports more stable cash generation than one-off equipment deliveries. With a market cap of $1.879 billion and a share price of 55.25 SEK as of August 20, 2026, the company’s valuation implies that investors expect its cash flow discipline to balance capital-intensive hardware deployments with higher-margin software and services. The quantified relationship between a mid-50s SEK share price, a 7.10 percent year-to-date performance and a sub-$2 billion market cap frames Elekta as a potential steady compounder rather than a high-growth, high-volatility name.
Peer and sector perspective
Within the broader cancer care technology sector, Elekta competes against larger US and European medical technology companies that often command higher market capitalizations and price-to-earnings ratios. The $1.879 billion market cap attributed to Elekta AB in recent comparative tables places the company below some diversified peers, suggesting that part of the investment thesis hinges on Elekta’s ability to grow faster than the sector average to narrow that valuation gap. For many investors, the mid-range price of 55.25 SEK and the 7.10 percent gain since January 2026 illustrate that the market is cautiously rewarding Elekta’s progress but still pricing in execution risk.
A concrete comparison emerges when looking at Elekta’s mid-50s SEK share price versus the broader move in major indices and other healthcare names this year. While large-cap indices have delivered strong gains driven by technology and financials, Elekta’s 7.10 percent year-to-date performance appears more measured, reinforcing the narrative that investors see the stock as a specialized healthcare exposure rather than a momentum trade. The -0.99 percent five-day change, though modest, reflects sensitivity to macro risk and sector rotation, which can temporarily outweigh company-specific fundamentals even when order intake and installed base metrics are moving in a positive direction.
Radiotherapy systems as core product
Elekta’s core business centers on advanced radiotherapy systems and related software used to treat cancer, combining precision hardware with sophisticated treatment planning. The company’s flagship linear accelerator platforms are designed to deliver high-energy radiation beams with millimeter-level accuracy, while its software helps oncologists tailor dosing regimens to individual tumors and organs at risk. This hardware-plus-software model supports recurring income via service contracts, software licenses and upgrades, bolstering cash flow beyond initial equipment sales.
In practice, hospital and clinic customers often commit to multi-year agreements that include equipment maintenance, access to planning tools and continuous software updates, giving Elekta a degree of visibility on revenue and margins. For investors, the radiotherapy portfolio’s adoption and retention rates can be just as important as shipment volumes. A mid-50s SEK share price with a $1.879 billion market cap as of August 20, 2026, implies the market believes Elekta’s installed base and ongoing demand for radiotherapy treatments will continue to support this recurring model even as competition remains intense.
Stock level and investor view
As of the CBOE close on August 20, 2026, Elekta AB shares traded at 55.25 SEK, with a five-day performance of -0.99 percent and a year-to-date gain of 7.10 percent based on recent market data. This level sits comfortably within the range associated with a $1.879 billion market cap, giving investors a quantified reference point for evaluating upside or downside relative to expected earnings, cash flow and backlog conversion over the next few reporting periods.
Read more
Further details on Elekta AB’s financial profile, including its cash flow statement and valuation metrics, can be accessed via the latest market-data overviews that compile price history, market capitalization and segment-level financial indicators.
Investor Relations
Additional background on Elekta’s strategy, radiotherapy portfolio and financial reporting schedule is available through the company’s investor communications, which provide insight into management priorities, capital allocation and innovation initiatives in oncology technology.
Fact box
Company: Elekta AB (publ)
ISIN: SE0000163628
Ticker: EKTA
Exchange: CBOE Europe
Price (as of August 20, 2026, 11:25 a.m. ET): 55.25 SEK
Market cap: $1.879 billion (as of August 20, 2026)
Sector / Industry: Health care equipment - oncology and radiotherapy
Index membership: European mid-cap benchmark
